• Citer

Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial (Breast Cancer Research and Treatment, (2017), 165, 2, (329-341), 10.1007/s10549-017-4304-7)

par Cortes, Javier;Rugo, Hope H.S.;Awada, Ahmad ;Twelves, Chris;Perez, Edith A;Im, Seock–Ah –A;Gómez-Pardo, Patricia;Schwartzberg, Lee L.S.;Diéras, Veronique;Yardley, Denise;Potter, David D.A.;Mailliez, Audrey;Moreno-Aspitia, Alvaro;Ahn, Jin Seok;Zhao, Carol;Hoch, Ute;Tagliaferri, Mary;Hannah, Alison L;O’Shaughnessy, Joyce
Référence Breast cancer research and treatment, 165, 2, page (329-341)
Publication Publié, 2017-09

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

The text in panel B of Fig. 1 (progression-free survival for patients with stable, treated brain metastases) was incorrectly labeled as mOS instead of mPFS. All other values and labels are correct. The corrected Figure 1 is given in this erratum.